Given the growing evidence that obesity is associated with increased cardiovascular risk, a recent study assessed the impact of semaglutide on cardiovascular outcomes in patients who are overweight or obese but do not have diabetes. Not only did semaglutide reduce the risk of cardiovascular death, myocardial infarction, and stroke by 20 percent, but it also significantly reduced the risk of developing diabetes. Dive further into the findings and implications with Dr. Carol Wysham and study author Dr. Michael Lincoff.
Managing the Diabetic Athlete
Screening, Diagnosis and Early Treatment for Diabetes and Pregnancy
After the Diet: Mindful Integration of Food and Behavior in Diabetes Management
How Stress Factors Into Diabetes Management
New Treatment Algorithm for Type 2 Diabetes
Immune Interventions for Type 1 Diabetes
Choosing Between Insulin and Incretin Therapies
Pediatric Diabetes Research
Approaching Patients with Diabetes from a Behavioral Perspective
Where Do SGLT-2s Fit in the Treatment of Diabetes?
Healthcare Reform and Implications for the Treatment of Diabetes
Managing Diabetic Patients with Peripheral Neuropathy
The Centers for Disease Control’s Approach to Prevention of Diabetes
Diabetes Research: Hope for a Cure in Stem Cells?
Do We Need to Temper our Enthusiasm for Incretin-Based Therapy?
Do Women With Diabetes Have a Greater Risk of Cardiovascular Disease?
Glycemic Control and Macrovascular Outcomes in Patients with Diabetes Using the Archimedes Model
The Role of Incretins for In-Hospital Management
The Need to Preserve Beta Cell Function Early
Current Guidelines for Inpatient Care of Patients With Diabetes
Create your
podcast in
minutes
It is Free
RenaissanceOnlineRadio.com
Men in Lead Aprons
Denver Underground
Exercise: Learn To Love (Or At Least Like) It
NASACast Video